VIP and PACAP in pain and inflammation

Trends in Pharmacological Sciences

Volumn 21, Issue 2, 2000, Pages 57-

  Said, S I ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANTIINFLAMMATORY ACTIVITY; BRONCHOSPASM; INFLAMMATION; LETTER; LUNG EDEMA; NEUROPROTECTION; PAIN; PRIORITY JOURNAL;

EID: 0033970248     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0165-6147(99)01427-3     Document Type: Letter

References (9)

1. T. Dickinson S.M. Fleetwood-Walker VIP and PACAP: very important in pain? Trends Pharmacol. Sci. 20 1999 324 329
2. T. Dickinson The role of VIP/PACAP receptor subtypes in spinal somato-sensory processing in rats with an experimental peripheral mononeuropathy Neuropharmacology 38 1999 167 180
3. S.I. Said Antiinflammatory actions of VIP in the lungs and airways S.I. Said Pro-Inflammatory and Anti-Inflammatory Peptides 1998 Marcel Dekker 345 361
4. D.E. Brenneman Activity-dependent neurotrophic factor: structure–activity relationships of femtomolar-acting peptides J. Pharmacol. Exp. Ther. 285 1998 619 627
5. S.I. Said Glutamate toxicity in the lung and neuronal cells: prevention or attenuation by VIP and PACAP Ann. New York Acad. Sci. 865 1998 226 237
6. M. Delgado Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-α and IL-6 J. Immunol. 162 1999 1200 1205
7. R.P. Mohney Galanin and vasoactive intestinal peptide messenger RNAs increase following axotomy of adult sympathetic neruons J. Neurobiol. 25 1994 108 118
8. T. Hökfelt Messenger plasticity in primary sensory neurons following axotomy and its functional implications Trends Neurosci. 17 1994 22 30
9. S.I. Said VIP and messenger plasticity Trends Neurosci 17 1994 339